| Date | Title | Description |
| 19.03.2025 | Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates | MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a M... |
| 24.10.2022 | Genenta Provides First Half 2022 Business Update and Financial Results | Current dose escalation study data shows a median overall survival of 17 months
Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimen Cash and cash equivalents of €34.7 million as of June 30, 2022, providing a c... |
| 24.10.2022 | Genenta Provides First Half 2022 Business Update and Financial Results | Current dose escalation study data shows a median overall survival of 17 months
Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a ca... |
| 05.10.2022 | Genenta to Present at Upcoming Scientific and Investor Conferences | MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and s... |
| 05.10.2022 | Genenta to Present at Upcoming Scientific and Investor Conferences | /EIN News/ -- MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 07.09.2022 | Genenta to Present at Upcoming Investor Conferences | MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and ... |
| 13.05.2022 | Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA | MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be pres... |
| 04.05.2022 | Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme | No dose limiting toxicity observed in previous three dose level cohorts
Represents a 50% higher dose than highest prior level
Update of guidance for trial
MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: ... |
| 04.05.2022 | Genenta Files Annual Report on Form 20-F for Fiscal Year 2021 | MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today... |
| 02.05.2022 | Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma | MILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces th... |
| 27.04.2022 | Genenta Announces Nomination of Mark A. Sirgo as Chair | 35 years industry experience including as CEO and founder of public company
Stephen Squinto steps down as Chair for new role
MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biot... |
| 20.04.2022 | Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors | MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced ... |
| 15.12.2021 | Genenta Announces Pricing of Upsized Initial Public Offering | MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the... |
| 14.12.2021 | Genenta Announces Pricing of Upsized Initial Public Offering | MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the... |
| 16.11.2021 | Genenta To Present Updated Phase I/II Data At Upcoming Scientific Congresses SNO AND ASH | MILAN, Italy and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced toda... |
| 11.11.2021 | Genenta Announces Filing of Registration Statement for Proposed Initial Public Offering | MILAN, Italy and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced toda... |
| 10.11.2021 | Genenta Announces Filing of Registration Statement for Proposed Initial Public Offering | MILAN, Italy and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced toda... |
| 30.09.2021 | Genenta Strengthens Senior Management With Key Strategic Appointments | Gaurav Shah, Brad Loncar and Alec Ross appointed as strategic advisors
Barbara Regonini joins recently hired CFO, Richard Slansky, completing senior financial management team
MILAN, Italy and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Gen... |
| 03.05.2021 | Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member | MILAN, Italy and NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announces that Richard Slansky ... |
| 05.01.2021 | Genenta to Take Part in Gene Therapy Panel and Two Virtual Investor Events in January 2021 | MILAN, Italy and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that Prof. Luigi Nal... |
| 23.11.2020 | Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman | MILAN, Italy and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem progenitor cell gene therapy for cancer (Temferon™), announced that high... |
| 16.11.2020 | Genenta's Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme | MILAN, Italy and NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), presents new p... |
| 30.09.2020 | Genenta to present preliminary Phase I/II clinical data on Temferon™ in glioblastoma multiforme at Chardan's 4th Annual Genetic Medicines Conference | MILAN, Italy and NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that it will presen... |
| 11.09.2019 | Genenta Science Raises €13.2M in Funding | Genenta Science, a Milan, Italy-based clinical-stage biotechnology company pioneering the development of hematopoietic stem cell gene therapies for cancer, closed its €13,2M third funding round.
The round, which brought total funding raised... |
| 17.09.2017 | Genenta Raises $8.4M in Second Financing | Genenta Science, a Milan, Italy-based biotech company committed to the development and commercialization of a hematopoietic stem cell gene therapy for tumors treatment, closed an $8M (€7M) Series B financing.
The round, which brings the tot... |
| 13.09.2017 | Martin Shkreli suddenly changes his tune on Clinton threat; Genenta adds $8M for gene therapy R&D | ⇨ Looking to stay out of jail ahead of his sentencing on three convictions on felony fraud charges, Martin Shkreli has apologized to the judge in his case for his “awkward attempt at humor” in his Facebook posting offering t... |
| 19.01.2017 | GSK R&D vet Russo jumps to Genenta, takes a lead role in developing a new gene therapy | Carlo Russo, Genenta
GSK vet Carlo Russo is joining up with some of his former gene therapy colleagues, taking the chief medical officer’s role at Milan-based Genenta Science.
Russo is coming over directly from Adverum... |
| 16.09.2016 | Genenta and OSR Sign Collaboration Deal with Amgen | Venture capital backed Genenta Science (Milan, Italy) and San Raffaele Hospital and Scientific Institute (Ospedale San Raffaele, OSR) announced a strategic collaboration with biotech giant Amgen (NASDAQ: AMGN) to explore hematopoietic stem ... |
| 03.09.2015 | Genenta Science, Tiziana Mattioni Joins as COO | Genenta Science, a Milan, Italy-based biotech company focused on hematopoietic stem cell gene therapy, added Tiziana Mattioni, Ph.D. as its Chief Operating Officer.
Dr. Mattioni comes to Genenta Science from Merck Serono, a division in Merc... |
| 06.03.2015 | Italy's Genenta Science raises $11M for gene therapy program at TIGET | Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.
Genenta CEO Pier... |
| 05.03.2015 | Genenta Science Closes €10M Series A Financing | Genenta Science, a Milan, Italy-based biotech startup, closed its €10m ($11m) Series A financing.
The round was led by Banca Esperia, the private bank of Mediobanca (MB:IM) and Mediolanum (MED:IM), with participation from entrepreneurs, man... |
| 23.01.2015 | Genenta Science Raises €6.2M in First Tranche of Series A Funding | Genenta Science, a Milan, Italy-based biotech startup, raised €6.2m ($7.2m) in the first tranche of its Series A funding.
Backers in the round, which is expected to close at €10m, included Banca Esperia, Mediolanum as well as private entrep... |
